Pesquisas alternativas:
oil company » oil companies (Expandir a Pesquisa)
company ha » company has (Expandir a Pesquisa), company a (Expandir a Pesquisa), company da (Expandir a Pesquisa)
cell car » cell ca (Expandir a Pesquisa), cell ca2 (Expandir a Pesquisa), cell can (Expandir a Pesquisa)
a newts » _ newts (Expandir a Pesquisa), a news (Expandir a Pesquisa), a newt (Expandir a Pesquisa)
ha ngoc » pham ngoc (Expandir a Pesquisa), bao ngoc (Expandir a Pesquisa)
l omer » al omer (Expandir a Pesquisa), b omer (Expandir a Pesquisa), e omer (Expandir a Pesquisa)
omer a » omer _ (Expandir a Pesquisa)
car j » carr j (Expandir a Pesquisa), acar j (Expandir a Pesquisa), car _ (Expandir a Pesquisa)
j new » a new (Expandir a Pesquisa), _ new (Expandir a Pesquisa), 2 new (Expandir a Pesquisa)
3 oil » 3 oils (Expandir a Pesquisa), _ oil (Expandir a Pesquisa), l oil (Expandir a Pesquisa)
A mostrar 1 - 20 resultados de 92 para a pesquisa '(( j l omer a newts ) OR ((( e cell car j new ) OR ( 3 oil company ha ngoc ))))', tempo de pesquisa: 1.01seg Refinar resultados
Smart CARs Engineered for Cancer Immunotherapy
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts

CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins
CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy

The Emergence of Universal Immune Receptor T Cell Therapy for Cancer
P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)
De novo-designed transmembrane domains tune engineered receptor functions

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Adenovirus Binding to the Coxsackievirus and Adenovirus Receptor or Integrins Is Not Required To Elicit Brain Inflammation but Is Necessary To Transduce Specific Neural Cell Types

A Metabolism Toolbox for CAR T Therapy
Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids

L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice
Molecular epidemiology of 58 new African human T-cell leukemia virus type 1 (HTLV-1) strains: identification of a new and distinct HTLV-1 molecular subtype in Central Africa and in Pygmies.

Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)
CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence

B-cell Maturation Antigen is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa